Smith & Nephew stock trades steady as surgical portfolio supports earnings

Smith & Nephew stock is backed by a long-established position in medical devices, with the London based group (ISIN GB0009223206) reporting higher revenue and operating profit in its latest full year figures. According to the companys annual report for fiscal 2024, revenue reached approximately $5.5 billion, reflecting growth compared with the previous year as its orthopedics and sports medicine businesses continued to recover from earlier pandemic related disruption. The numbers highlight how the FTSE listed company remains focused on profitability while funding new product launches in areas such as surgical reconstruction.

Revenue up year on year

In its fiscal 2024 results, Smith & Nephew disclosed total revenue of around $5.5 billion, up from roughly $5.2 billion in 2023, a year on year increase in the mid single digit percentage range. This growth has been driven by procedure volumes returning in key markets and by portfolio development across orthopedics, sports medicine and wound management. The revenue performance illustrates that the company is managing to grow the top line while navigating pricing pressure and hospital budget constraints in several regions.

Operating profit also rose compared with the prior year, supported by a combination of higher sales and ongoing efficiency measures. For fiscal 2024, underlying trading profit was in the region of $900 million, representing a trading margin in the mid teens as a percentage of revenue. That margin level is broadly consistent with the previous year and signals that Smith & Nephew has been able to offset cost inflation through productivity initiatives and targeted price actions. For investors, the ability to maintain margins while investing in research and development is a key element of the equity story.

Around mid teens margin level

The trading margin in fiscal 2024, at around the mid teens level, reflects both the strength of the companys established implants business and the growing contribution from sports medicine. Orthopedics, which includes hip and knee implants, remains the largest segment by sales and has benefited from increased surgical volumes as healthcare systems address deferred procedures. Sports medicine and ENT has delivered faster growth, with management pointing to demand for minimally invasive solutions in soft tissue repair and ligament reconstruction.

Within wound management, Smith & Nephew continues to expand advanced wound care products for chronic wounds such as diabetic foot ulcers and venous leg ulcers. The segment contributes a significant share of revenue and margins, helping to diversify earnings beyond orthopedics. The company has also been directing capital expenditure towards manufacturing upgrades and digital tools to support hospital customers, which over time can help sustain profitability even as competition in medical devices remains intense.

Orthopedics and sports medicine product focus

One representative product area for Smith & Nephew is its portfolio of knee and hip implants used in joint replacement surgery. These implants are designed to help patients regain mobility and reduce pain, and they form a substantial part of the orthopedics segment. Revenue from orthopedics is a major portion of the companys total sales, and the segment benefits from demographic trends as aging populations in North America, Europe and Asia drive demand for joint replacement procedures.

Sports medicine devices, including anchors, sutures and arthroscopic instruments used in ligament and tendon repair, have been growing faster than some more mature product lines. Hospitals and clinics value solutions that allow minimally invasive procedures with shorter recovery times, which supports demand for Smith & Nephews sports medicine offerings. By continuing to innovate in these product categories, the company aims to differentiate its portfolio and defend market share against global competitors.

Smith & Nephew stock and market context

Smith & Nephew is listed on the London Stock Exchange, where its shares trade in pence and are included in the FTSE indices that track major UK companies. The group has a market capitalization in the billions of pounds, reflecting its status as a key player in the global medical devices sector. Over the past year, the share price has fluctuated within a range that corresponds to investors reassessing growth prospects in orthopedics and wound care, as healthcare systems continue to normalize after earlier disruptions.

For holders of Smith & Nephew stock, the combination of steady margins, revenue growth and exposure to structural trends in surgery and chronic care forms the core of the investment case. The companys balance between mature implant lines and newer sports medicine technologies means that future performance will be influenced both by how quickly procedure volumes grow and by the success of new product launches. Dividend payments have historically been part of the return profile, and ongoing cash flow from operations provides flexibility for continued investment in research, development and selective acquisitions.